Feature | Implantable Cardioverter Defibrillator (ICD) | July 02, 2015

Boston Scientific Initiates Global Study of Emblem Subcutaneous Implantable Defibrillator

Study examines primary prevention in patients with low ejection fraction

Boston Scientific, Emblem, S-ICD, UNTOUCHED study, TV-ICDs, MADIT-RIT study

July 2, 2015 - Boston Scientific has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the Emblem subcutaneous implantable defibrillator (S-ICD). The device is indicated for primary prevention of sudden cardiac death in the setting of severely reduced cardiac function (left ventricular ejection fraction </= 35 percent).

Primary prevention patients do not have a previously documented life-threatening arrhythmic event, but are at risk of sudden cardiac death and thereby indicated to receive an implantable defibrillator. This group of patients represents the highest proportion of patients that are implanted with transvenous ICD (TV-ICDs) devices today in the United States and European Union. 

In order to further demonstrate the usefulness of the S-ICD System in this particular patient population, the UNTOUCHED study will compare outcomes during an 18-month follow-up period to objective performance criteria derived from the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) study. The landmark MADIT-RIT study evaluated shock rates in 1,500 patients implanted with TV-ICD devices and is one of the largest randomized trials to assess shock reduction strategies for TV-ICD devices.

"The MADIT-RIT trial demonstrated that standardized programming using higher rate cutoffs and longer delays to therapy reduces the incidence of inappropriate shocks for TV-ICDs," said Lucas Boersma, M.D., EU principal investigator and electrophysiologist at St. Antonius Hospital, The Netherlands. "The UNTOUCHED trial will examine the incidence of all-cause shocks when using the EMBLEM S-ICD System with standardized therapy settings similar to MADIT-RIT."

The first patient enrolled in the global, multi-site, prospective, non-randomized UNTOUCHED study received an Emblem implant by Craig Barr, M.D., cardiologist at Russells Hall Hospital in Dudley, England. The study will enroll a minimum of 2,015 patients at up to 200 sites worldwide. Enrollments in the United States will begin later this summer.

"In the published data to date, we have observed S-ICD devices demonstrate comparable inappropriate shock rates for arrhythmias to TV-ICDs," said Michael Gold, M.D., Ph.D., U.S. principal investigator and chief of cardiology and the Michael E. Assey professor of medicine at Medical University of South Carolina, Charleston. "Ideally, this trial will demonstrate S-ICD devices can either meet or improve upon the inappropriate shock rates experiences with TV-ICDs in MADIT-RIT within this large patient population."

The Emblem S-ICD system received CE mark earlier this year and was approved by the U.S. Food & Drug Administration (FDA) in March of 2015. The device launched in Europe starting in May, and became commercially available in the United States in June, in preparation for a planned full U.S. launch during the third quarter of 2015.

For more information: www.bostonscientific.com


Related Content

News | Sudden Cardiac Arrest

September 9, 2022 — The probability of surviving sudden cardiac arrest outside hospital has more than doubled in 30 ...

Home September 09, 2022
Home
News | Sudden Cardiac Arrest

September 2, 2022 — A restrictive oxygenation target in comatose patients resuscitated after out-of-hospital cardiac ...

Home September 02, 2022
Home
News | Sudden Cardiac Arrest

September 1, 2022 — A target blood pressure of 77 mmHg provides no benefit to survival or neurological outcome in ...

Home September 01, 2022
Home
News | Sudden Cardiac Arrest

August 26, 2022 — Researchers in the Smidt Heart Institute at Cedars-Sinai are one step closer to identifying patients ...

Home August 26, 2022
Home
News | Sudden Cardiac Arrest

July 28, 2022 — In 2020, a team of cardiovascular experts from the Lankenau Institute for Medical Research (LIMR), part ...

Home July 28, 2022
Home
News | Sudden Cardiac Arrest

July 19, 2022 — Research by GlobalData has highlighted the startling difference between the forecast number of diagnosed ...

Home July 19, 2022
Home
News | Sudden Cardiac Arrest

July 13, 2022 — Adults with abnormal heart metabolism are up to three times more likely to experience life-threatening ...

Home July 13, 2022
Home
News | Sudden Cardiac Arrest

July 11, 2022 — Rod was diagnosed with cancer, but it wasn’t his most urgent medical issue. A few months after that ...

Home July 12, 2022
Home
News | Sudden Cardiac Arrest

June 3, 2022 — Texas Children's Hospital patient Garrett Richardson, 21, is alive today because his quick-thinking ...

Home June 03, 2022
Home
News | Sudden Cardiac Arrest

May 13, 2022 — The MemorialCare Heart & Vascular Institute at Long Beach Medical Center has been designated the only ...

Home May 13, 2022
Home
Subscribe Now